DK3793573T3 - Delmængde af humane naturlige dræberceller med forbedrede antistof-rettede immunresponser - Google Patents

Delmængde af humane naturlige dræberceller med forbedrede antistof-rettede immunresponser Download PDF

Info

Publication number
DK3793573T3
DK3793573T3 DK19803497.7T DK19803497T DK3793573T3 DK 3793573 T3 DK3793573 T3 DK 3793573T3 DK 19803497 T DK19803497 T DK 19803497T DK 3793573 T3 DK3793573 T3 DK 3793573T3
Authority
DK
Denmark
Prior art keywords
immune responses
natural killer
killer cell
cell subset
human natural
Prior art date
Application number
DK19803497.7T
Other languages
Danish (da)
English (en)
Inventor
Santos Gary Dos
Guy Dipierro
Original Assignee
Indapta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indapta Therapeutics Inc filed Critical Indapta Therapeutics Inc
Application granted granted Critical
Publication of DK3793573T3 publication Critical patent/DK3793573T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Developmental Biology & Embryology (AREA)
DK19803497.7T 2018-05-14 2019-05-14 Delmængde af humane naturlige dræberceller med forbedrede antistof-rettede immunresponser DK3793573T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862671358P 2018-05-14 2018-05-14
PCT/US2019/032318 WO2019222293A1 (en) 2018-05-14 2019-05-14 Subsets of human natural killer cells with enhanced antibody-directed immune responses

Publications (1)

Publication Number Publication Date
DK3793573T3 true DK3793573T3 (da) 2024-11-25

Family

ID=68541145

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19803497.7T DK3793573T3 (da) 2018-05-14 2019-05-14 Delmængde af humane naturlige dræberceller med forbedrede antistof-rettede immunresponser

Country Status (10)

Country Link
US (1) US20210187025A1 (https=)
EP (2) EP4474391A3 (https=)
JP (2) JP2021522839A (https=)
CN (1) CN112839666A (https=)
AU (1) AU2019271146A1 (https=)
CA (1) CA3099806A1 (https=)
DK (1) DK3793573T3 (https=)
ES (1) ES2993360T3 (https=)
PT (1) PT3793573T (https=)
WO (1) WO2019222293A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10066207B2 (en) 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
CN110546265A (zh) 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
KR20230088306A (ko) * 2020-04-22 2023-06-19 인답타 세라뷰틱스 인코포레이티드 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법
US11591381B2 (en) 2020-11-30 2023-02-28 Crispr Therapeutics Ag Gene-edited natural killer cells
AU2021392032A1 (en) 2020-12-03 2023-06-22 Century Therapeutics, Inc. Genetically engineered cells and uses thereof
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable
WO2022144632A1 (en) 2020-12-30 2022-07-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
AU2022254689A1 (en) * 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a her2 targeted antibody
JP2024515169A (ja) * 2021-04-08 2024-04-05 アルティヴァ バイオセラピューティクス インコーポレイテッド Ｎｋ細胞およびｃｄ２０標的抗体を用いた癌治療
AU2022253256A1 (en) * 2021-04-08 2023-11-16 Artiva Biotherapeutics, Inc. Treatment of cancer with nk cells and a cd38-targeted antibody
JP2024513958A (ja) * 2021-04-08 2024-03-27 アルティヴァ バイオセラピューティクス インコーポレイテッド Ｎｋ細胞およびｅｇｆｒ標的抗体を用いた癌治療
CN117715647A (zh) * 2021-04-08 2024-03-15 埃迪瓦生物治疗公司 用nk细胞和cd38靶向抗体治疗癌症
WO2022226130A1 (en) * 2021-04-21 2022-10-27 Indapta Therapeutics, Inc. Methods of treatment and dosing of natural killer cell compositions
CN115369086B (zh) * 2022-02-22 2023-05-12 北京景达生物科技有限公司 一种nk细胞扩大培养的培养方案
CN116679065B (zh) * 2023-07-31 2023-11-14 北京大学人民医院 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US6016891A (en) 1998-08-10 2000-01-25 Sava; John G. Tree stand harness system
WO2005118854A1 (en) * 2004-06-01 2005-12-15 Centre Hospitalier Regional Et Universitaire De Tours Fcgr3a gebotype and methods for evaluating treatment response to non-depleting antibodies
DE602005016683D1 (de) * 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
JP5282040B2 (ja) * 2007-09-28 2013-09-04 オリンパス株式会社 Ｆｃ受容体遺伝子導入ＮＫ細胞を用いた抗体依存性細胞傷害のアッセイ方法
WO2012061814A1 (en) 2010-11-05 2012-05-10 Transgenomic, Inc. Pcr primers and methods for rapid and specific genotyping
US10066207B2 (en) * 2012-04-18 2018-09-04 Board Of Trustees Of Michigan State University Natural killer cells with enhanced immune response
US10813952B2 (en) * 2014-11-14 2020-10-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors
CN110546265A (zh) * 2017-02-09 2019-12-06 因达普塔治疗公司 工程化自然杀伤(nk)细胞及其组合物和方法

Also Published As

Publication number Publication date
JP2021522839A (ja) 2021-09-02
JP2024096956A (ja) 2024-07-17
EP3793573A1 (en) 2021-03-24
EP4474391A2 (en) 2024-12-11
US20210187025A1 (en) 2021-06-24
EP3793573B1 (en) 2024-10-23
CA3099806A1 (en) 2019-11-21
EP3793573A4 (en) 2022-01-26
EP4474391A3 (en) 2025-02-26
WO2019222293A1 (en) 2019-11-21
ES2993360T3 (en) 2024-12-27
CN112839666A (zh) 2021-05-25
AU2019271146A1 (en) 2020-12-10
PT3793573T (pt) 2024-11-05

Similar Documents

Publication Publication Date Title
DK3793573T3 (da) Delmængde af humane naturlige dræberceller med forbedrede antistof-rettede immunresponser
EP3562492A4 (en) GENETICALLY MODIFIED NATURAL KILLER CELLS
IL284809A (en) Humanized t cell mediated immune responses in non human animals
IL269553A (en) Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
IL258666A (en) Natural killer cells and ilc3 cells and uses thereof
DK3581190T3 (da) Manipulerede naturlige dræberceller og anvendelser deraf
EP3740152A4 (en) SURGICAL PLATFORM EQUIPPED WITH ADJUSTABLE ARM SUPPORTS
LT3500593T (lt) T ląstelių receptoriai ir imuninė terapija juos naudojant
DK3707159T3 (da) Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf
EP3443506C0 (fr) Neurone artificiel
DK3317401T3 (da) Modificerede naturlige dræberceller og naturlige dræbercellelinjer med øget cytotoksicitet
HUE049046T2 (hu) Mesterséges napfény világító
DK3507373T5 (da) Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1
EP4268907C0 (en) Adjustable Weight Russian Dumbbell
PL3114145T3 (pl) Przeciwciała przeciw ludzkiemu białku pomocniczemu receptora interleukiny-1 (il1rap) i ich zastosowania
IL282901A (en) Methods for isolating and expanding cells
IL283813A (en) Stress disorder training
EP3573464A4 (en) B CELL ENGINEERING
IL270876A (en) Novel oncolytic viruses for sensitizing tumor cells to killing by natural killer cells
MA54444A (fr) Remplissage de gazon artificiel et gazon artificiel
IL285039A (en) Compositions and methods for stimulating natural killer cells
EP3813611A4 (en) TOASTER
EP3850744A4 (en) MICRO INVERTER AND CONTROL UNIT
EP3837468C0 (en) SOLAR SIMULATOR
EP3898701A4 (en) COMBINATION THERAPY OF WEAPONS AND NATURAL KILLER CELLS